Yanagi Teruki, Kitamura Shinya, Hata Hiroo
Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Front Oncol. 2018 Mar 23;8:79. doi: 10.3389/fonc.2018.00079. eCollection 2018.
Cutaneous squamous cell carcinoma (SCC) is one of the common cancers in Caucasians, accounting for 20-30% of cutaneous malignancies. The risk of metastasis is low in most patients; however, aggressive SCC is associated with very high mortality and morbidity. Although cutaneous SCC can be treated with surgical removal, radiation and chemotherapy singly or in combination, the prognosis of patients with metastatic SCC is poor. Recently, the usage of immune checkpoint blockades has come under consideration. To develop effective therapies that are less toxic than existing ones, it is crucial to achieve a detailed characterization of the molecular mechanisms that are involved in cutaneous SCC pathogenesis and to identify new drug targets. Recent studies have identified novel molecules that are associated with SCC carcinogenesis and progression. This review focuses on recent advances in molecular studies involving SCC tumor development, as well as in new therapeutics that have become available to clinicians.
皮肤鳞状细胞癌（SCC）是白种人中常见的癌症之一，占皮肤恶性肿瘤的20%-30%。大多数患者发生转移的风险较低；然而，侵袭性SCC与极高的死亡率和发病率相关。尽管皮肤SCC可以通过手术切除、放疗和化疗单独或联合治疗，但转移性SCC患者的预后较差。最近，免疫检查点阻断剂的使用已被纳入考虑范围。为了开发比现有疗法毒性更小的有效疗法，详细表征皮肤SCC发病机制中涉及的分子机制并确定新的药物靶点至关重要。最近的研究已经鉴定出与SCC致癌作用和进展相关的新分子。本综述重点关注SCC肿瘤发生的分子研究的最新进展以及临床医生可获得的新疗法。
